Testing a new vaccine for Shigellosis in infants

Safety and Immunogenicity of a Second Generation Shigella Bioconjugate Vaccine: a Phase II Randomized, Controlled, and Blinded Study in 9-month-old Infants

This study is testing a new vaccine for Shigellosis in 9-month-old infants to see if it is safe and how well it helps their immune system.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 110 (estimated)
• Ages: 8 Months to 10 Months
• Sex: All
• Sponsor: LimmaTech Biologics AG (industry)
• Drugs / interventions: prednisone
• Locations: 1 site (Kisumu)
• Trial ID: NCT06523231 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and immune response of the Shigella4V2 bioconjugate vaccine in 9-month-old infants. Participants will be randomly assigned to receive one of two different doses of the vaccine or a control vaccine, following a two-dose schedule. The vaccine is designed to protect against Shigellosis by targeting the most common Shigella serotypes. The study aims to confirm previous findings and determine the optimal dosage for infants.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy infants aged 9 months who have completed their routine primary vaccinations.

Not a fit: Patients who are not 9 months old or those with serious underlying health conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this vaccine could significantly reduce the incidence of Shigellosis in infants, improving child health outcomes.

How similar studies have performed: Previous studies on similar vaccine approaches have shown promise, but this specific vaccine is being tested for the first time in this population.

Eligibility criteria

Inclusion Criteria:

* Female or male aged 9 months (± 1 month) old at the time of the first vaccination.
* Born full-term (i.e., after a gestation period of 37 to less than 42 full weeks).
* Healthy by medical history, laboratory findings and physical examination before entering into the study (Participants with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
* Seronegative for HIV, hepatitis B and C (as per screening laboratory tests)
* Resident of Siaya County during the whole trial period.
* Previously completed routine primary vaccinations (6,10 and 14 weeks or thereabouts) to the best knowledge of the participant's parent/guardian. This information will be abstracted from the maternal and child health booklet. All the participant's parent/guardian will be requested to carry this booklet whenever they visit the clinic.
* Signed/thumb printed informed consent, in accordance with local practice, provided by participants' parents or guardian who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Demonstrated comprehension (by the parent/guardian) of the protocol procedures through passing a written/verbal comprehension test with a score of 80% or higher (at least 10 out of 12 questions).

Exclusion Criteria:

* Any clinically significant deviation from the normal range in biochemistry or hematological blood tests.
* Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study.
* Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
* Any confirmed or suspected immunosuppressive or immune-deficient condition.
* Systemic administration of corticosteroids (PO/IV/IM): prednisone ≥20 mg/day, or equivalent for more than 14 consecutive days from birth within 90 days prior to informed consent. Inhaled except for doses \> 800 mg/day and topical steroids are allowed.
* Administration of antineoplastic or radiotherapy from birth / within 90 days prior to informed consent. Participants may be on chronic or as needed medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition.
* Known exposure to Shigella during lifetime of the study participant
* Concurrently participating in another clinical study, or participation in the preceding month, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
* Acute illness with or without fever is a temporary exclusion criterium. Positive malaria test is a temporary exclusion criterion.
* History of any malignancy of lymphoproliferative disorder.
* Parent/guardian known to be part of study personnel or being a close family member to the personnel conducting this study.
* Previous history of significant persistent neutropenia, or drug related Neutropenia.
* Weight-for-age Z score less than -3 Standard Deviations (SD).
* History of any chronic or progressive disease (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease) that according to judgment of the investigator could interfere with the study outcomes or pose a threat to the participant's health.
* Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine.
* Any medical, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the parent's/guardian's ability to give informed consent, increases the risk to the potential participant because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

Where this trial is running

Kisumu

• KEMRI - Center for Global Health Research — Kisumu, Kenya (RECRUITING)

Study contacts

• Principal investigator: Richard Omore, PhD — KEMRI - Center for Global Health Research
• Study coordinator: Richard Omore, PhD

Conditions: Shigellosis